Astra Zeneca and Eli Lilly extends the cooperation in the field of Alzheimer’s by jointly developing the drug candidate MEDI1814. Studies are currently in progress in phase-1 and is reported to have the potential to transform the treatment of Alzheimer’s disease. It is clear from a press release.
The relevant drug candidate is within astrazeneca’s IMED Biotech business. This part of Astra Zeneca focuses on the next generation of medicines.
The two companies have a partnership to combat Alzheimer’s in the form of the drug candidate AZD3293, which is a so-called BACE inhibitor, under development in the two phase-3 studies.
In connection with astrazeneca’s strategic update in 2014 was reported to AZD3293 have a potential for a non-risk-adjusted toppförsäljning of about 5 billion dollars. The drug candidate would then have a potential to slow the development of Alzheimer’s disease.
The enhanced cooperation entitles Astra Zeneca to a upfrontbetalning about 30 million dollars in the fourth quarter.
No comments:
Post a Comment